Brugada criteria for wide-complex tachycardia (also searched with possessive/alternate eponym spelling where applicable, ICD-10: I47.2) is a standardized, highly specific 4-step electrocardiographic algorithm developed to differentiate ventricular tachycardia (VT) from supraventricular tachycardia (SVT) with aberrant interventricular conduction or preexisting bundle branch block1. When faced with a wide-complex tachycardia—defined as a rhythm with a QRS duration exceeding 120 milliseconds—distinguishing between ventricular and supraventricular etiologies is paramount, as misdiagnosis and subsequent administration of AV nodal blocking agents (such as verapamil or adenosine) to a patient with ventricular tachycardia can precipitate catastrophic hemodynamic collapse, ventricular fibrillation, and cardiac arrest1. The Brugada algorithm relies on sequential evaluation of precordial lead morphology, R-to-S intervals, atrioventricular dissociation, and terminal QRS vector features to establish a definitive diagnosis and guide emergency therapeutic interventions1.

Etiology & Risk Factors

  • Structural Heart Disease: Prior myocardial infarction, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy (ARVC), and valvular heart disease represent primary substrates for monomorphic ventricular tachycardia presenting as wide-complex tachycardia1.
  • Electrolyte & Metabolic Derangements: Severe hypokalemia, hypomagnesemia, and acute hyperkalemia alter myocardial membrane resting potentials, predisposing vulnerable cardiac tissue to re-entrant ventricular arrhythmias1.
  • Proarrhythmic Drug Toxicity: Toxicity from class Ia (e.g., procainamide, quinidine), class Ic (e.g., flecainide, propafenone), or class III (e.g., amiodarone, sotalol) antiarrhythmic agents prolongs cardiac action potential duration and refractoriness, inducing widened QRS complexes and malignant ventricular rhythms1.
  • Genetically Inherited Channelopathies: Congenital long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), and short QT syndrome elevate baseline risk for sudden cardiac death and polymorphic wide-complex tachycardia1.
  • Acquired Conduction Abnormalities: Pre-existing bundle branch blocks (left bundle branch block or right bundle branch block) or accessory pathways (such as in Wolff-Parkinson-White syndrome with antidromic conduction) account for supraventricular tachycardia mimicking wide-complex tachycardia1.

Pathophysiology

Wide-complex tachycardia encompasses any cardiac rhythm exceeding 100 beats per minute with a QRS complex duration greater than 120 milliseconds. The fundamental pathophysiological dichotomy lies between supraventricular tachycardia with aberrant conduction (where depolarization propagates down the normal specialized His-Purkinje conduction system, albeit with functional block in one bundle branch) and ventricular tachycardia (where depolarization originates from an ectopic focus within the ventricular myocardium, propagating via slower cell-to-cell myocardial fiber conduction rather than the rapid Purkinje network). This slower myocardial activation accounts for the widened, bizarre QRS morphology, vector forces directed away from standard axes, and characteristic electrophysiological markers. The Brugada algorithm exploits these electrophysiological divergences by systematically testing for features impossible or unlikely in supraventricular conduction: total absence of RS complexes across all precordial leads (indicating uniform myocardial breakthrough), prolonged R-to-S intervals exceeding 100 milliseconds (reflecting delayed activation spread), atrioventricular dissociation (proving independent atrial and ventricular pacemakers), and specific morphological contours in leads V1–V2 and V6 that mirror classic right or left bundle branch block patterns peculiar to ventricular exit sites1.

Brugada criteria for wide-complex tachycardia — Pathophysiological Cascade & Clinical Flowchart 1 Wide-complex tachycardia on 12-lead ECG Rapid ventricular rhythm with QRS duration exceeding 120 milliseconds. 2 Evaluation of precordial RS complex absence Step 1 assesses whether precordial leads V1 through V6 lack an RS complex entirely. 3 Measurement of R-to-S interval duration Step 2 measures the interval from the onset of the R wave to the nadir of the S wave in precordial leads. 4 Assessment for atrioventricular dissociation Step 3 identifies independent P waves dissociated from QRS complexes. 5 Morphological pattern analysis & diagnosis Step 4 evaluates classic VT morphology in leads V1, V2, and V6 to confirm ventricular tachycardia.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients frequently present with acute palpitations, lightheadedness, presyncope, frank syncope, chest discomfort, dyspnea, or sudden hemodynamic deterioration. A history of prior myocardial infarction, coronary artery disease, or familial sudden cardiac death strongly favors ventricular tachycardia.
  • Physical Examination & Named Clinical Signs: Examination reveals tachycardia, variable blood pressure depending on ventricular rate and myocardial reserve, and potential signs of acute heart failure (pulmonary rales, elevated jugular venous pressure, peripheral edema). Clinical hallmarks of atrioventricular dissociation include fluctuating intensity of the first heart sound (S_1), cannon 'a' waves in the jugular venous pulse, and irregularly timed pulsations in the carotid arteries.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationStandard 12-lead electrocardiogram analyzed via the sequential 4-step Brugada algorithm to differentiate ventricular tachycardia from supraventricular tachycardia1.
Laboratory PanelSerum electrolytes (potassium, magnesium, calcium), complete blood count, cardiac biomarkers (troponin I/T), renal function panels, and baseline arterial blood gas or venous lactate to assess tissue perfusion and metabolic stress.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography to evaluate for cardiomegaly, pulmonary congestion, or acute heart failure; echocardiography (transthoracic or bedside point-of-care) to assess left ventricular ejection fraction, regional wall motion abnormalities, and structural heart disease.
ECG / Histopathology / ProceduralContinuous telemetry monitoring and 12-lead ECG documentation pre- and post-cardioversion; invasive electrophysiological study (EPS) in specialized settings for definitive mapping and ablation.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Step 1: Precordial RS ComplexAbsence of RS complex in all precordial leads (V1 through V6). If present, proceed to Step 2; if absent, diagnose ventricular tachycardia (sensitivity ~21%, specificity ~100%)1.
Step 2: R-to-S IntervalInterval from the onset of the R wave to the nadir of the S wave exceeding 100 milliseconds in any precordial lead. If present, diagnose VT; if absent, proceed to Step 3 (sensitivity ~66%, specificity ~98%)1.
Step 3: AV DissociationPresence of atrioventricular dissociation (independent P waves and QRS complexes). If present, diagnose VT; if absent, proceed to Step 4 (sensitivity ~82%, specificity ~98%)1.
Step 4: Morphology CriteriaMorphology criteria for VT present in leads V1–V2 and V6 (e.g., rabbit ear sign with taller left peak in V1, monophasic R or qR in V1, or QS/rS pattern in V6). If present, diagnose VT; if absent, diagnose SVT with aberrancy1.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Supraventricular Tachycardia with Aberrant ConductionPre-existing bundle branch block or functional rate-related aberrancy; satisfies none of the Brugada steps for ventricular origin; responds to vagal maneuvers or adenosine.
Antidromic Atrioventricular Re-entrant Tachycardia (WPW)Wide-complex tachycardia utilizing an accessory pathway for anterograde conduction; delta waves visible on baseline ECG; irregular wide complexes if pre-excited atrial fibrillation.
Pacemaker-Mediated TachycardiaWide QRS complexes driven by pacemaker spikes; interrogation of implantable cardioverter-defibrillator (ICD) or pacemaker confirms device malfunction or endless-loop tachycardia.
Toxicity-Induced Conduction DelaySevere sodium channel blockade (tricyclic antidepressant or class Ic overdose); marked QRS widening (>160 ms), rightward terminal axis (R wave in aVR), responding to sodium bicarbonate administration.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Assess airway, breathing, and circulation immediately. If the patient exhibits signs of hemodynamic instability (hypotension, altered mental status, acute heart failure, or ongoing chest pain), perform immediate synchronized direct-current cardioversion starting at 100 J biphasic (or escalated per advanced life support protocols) under adequate sedation. Ensure continuous pulse oximetry, cardiac telemetry, and immediate availability of resuscitation equipment and crash cart.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): For hemodynamically stable patients with confirmed or suspected ventricular tachycardia based on Brugada criteria, administer intravenous antiarrhythmic therapy:
    • Amiodarone: 150 mg IV administered over 10 minutes; may be repeated once if needed, followed by a maintenance infusion of 1 mg/min for the first 6 hours.
    • Procainamide: 20 to 50 mg/min IV infusion until the arrhythmia is suppressed, hypotension ensues, QRS duration increases by greater than 50%, or a maximum total dose of 17 mg/kg is reached (contraindicated in severe heart failure or prolonged QT).
    • Lidocaine: 1.0 to 1.5 mg/kg IV push; repeat doses of 0.5 to 0.75 mg/kg every 5 to 10 minutes up to a maximum total dose of 3 mg/kg, particularly effective in acute ischemic settings.
  • Surgical / Interventional Indications: Following acute stabilization, arrange urgent cardiology or electrophysiology consultation for coronary angiography, evaluation for implantable cardioverter-defibrillator (ICD) placement, or catheter ablation of arrhythmogenic myocardial substrates.
  • Nursing Care & Bedside Monitoring Considerations: Continuously monitor telemetry strips for rhythm transitions, frequent ventricular ectopy, or torsades de pointes. Maintain secure peripheral or central intravenous access, record serial 12-lead ECGs before and after pharmacological interventions, monitor blood pressure every 5 minutes during acute drug infusion, and ensure emergency airway management supplies remain at the bedside.

Complications & Prognosis

  • Acute Hemodynamic Collapse: Degeneration of sustained ventricular tachycardia into ventricular fibrillation or pulseless electrical activity (PEA), resulting in sudden cardiac arrest and cardiogenic shock.
  • Myocardial Ischemia: Increased myocardial oxygen demand coupled with compromised diastolic filling time can provoke or exacerbate acute coronary syndrome and acute decompensated heart failure.
  • Thromboembolic Events: Prolonged tachyarrhythmias and impaired ventricular contractility increase the risk of intraventricular mural thrombus formation and subsequent systemic embolization.
  • Prognostic Determinants: Long-term prognosis is dictated primarily by the underlying substrate (e.g., extent of coronary artery disease, left ventricular ejection fraction) and successful risk stratification, including secondary prevention via ICD implantation and antiarrhythmic medication optimization1,3.